ABSTRACT -Serum tissue polypeptide antigen (TPA) and plasma carclnoembryonlc antigen (CEA) were simultaneously measured In 108 patients with breast cancer, In 40 healthy women, and In 26 women with benign breast disease. TPA levels were elevated (0.09 JLg/ml or higher) In 53% of 19 patients with primary breast cancer, and CEA levels were elevated (2.5 ng/ml) In 21%. Among 67 patients with metastatic breast cancer, TPA and CEA levels were Increased In 70% and 61%, respectively. TPA was positive In 13% and CEA In 8% of the healthy women. CEA levels were not elevated In patients with benign breast disease, but levels of TPA were elevated In 27% of those studied. TP A was initially reported and characterized by Bjorklund and Bjorklund (1). Present in different types of malignant tumors, TP A is a component of the cellular endoplasmic reticulum and cell membrane. Biochemically, TPA is a single-chain polypeptide with a molecular weight of approximately 20,000 and contains predominately aspartic acid, glutamic acid, and leucine. By using a passive hemagglutination inhibition technique, investigators (1-3) have shown that the level of TP A was elevated in the sera of patients with various neoplastic diseases, including women with breast cancer. This is the report of our prospective study to evaluate the use of TP A in women with breast cancer. A CEA level obtained simultaneously at each TPA evaluation served as a standard of comparison. We (4) previously reported the study of CEA in patients with breast cancer.
TP A was initially reported and characterized by Bjorklund and Bjorklund (1) . Present in different types of malignant tumors, TP A is a component of the cellular endoplasmic reticulum and cell membrane. Biochemically, TPA is a single-chain polypeptide with a molecular weight of approximately 20,000 and contains predominately aspartic acid, glutamic acid, and leucine. By using a passive hemagglutination inhibition technique, investigators (1-3) have shown that the level of TP A was elevated in the sera of patients with various neoplastic diseases, including women with breast cancer. This is the report of our prospective study to evaluate the use of TP A in women with breast cancer. A CEA level obtained simultaneously at each TPA evaluation served as a standard of comparison. We (4) previously reported the study of CEA in patients with breast cancer.
MATERIALS AND METHODS
Of 108 women with breast cancer, 67 had metastatic disease and 19 had primary breast cancer without treatment. Breast cancer was histologically confirmed for all these patients. Blood samples were also obtained from our controls: 40 healthy women and 26 with benign breast disease. Twenty-two additional patients with breast cancer joined the follow-up program after their mastectomies; all were free of metastatic disease at the time the blood samples were procured.
Soft tissue metastasis was always confirmed by biopsy. Osseous or pulmonary metastases were documented by radiographic means, and hepatic or cerebral metastases were diagnosed by nuclear scans. Patients with tumors in the metastatic phase were generally treated with systemic therapy, such as ablative surgical procedures or chemotherapeutic modalities.
From still another 39 patients, serial blood samples were obtained to study the correlation between the clinical course of the breast cancer and the changes in CEA or TPA values. Modalities used were combination chemotherapy in 24 patients with 9 responders; 21 were treated by the combination of 5-£luorouracil and Cytoxan with or without prednisone, and 3 patients received combinations that included adriamycin. Eight patients underwent adrenalectomy with response in 2, and I additional patient responded to oophorectomy. Neither of the 2 patients receiving additional hormones responded, and all 4 given the combined treatment of adrenalectomy, 5-£luorouracil, and Cytoxan responded. From 18 patients, at least 2 samples were obtained I month apart; from another 21 patients, 3-5 samples were obtained at I-month intervals.
Objective tumor response was assessed by demonstrable regression or progression of measurable metastases by the criteria outlined by the Cooperative Breast Cancer Group (5); subjective improvement was not used as the sole criterion of improvement. Patients were further subdivided into groups with minimal or marked progression or regression for analyses of the results. Minimal changes were those seen either in patients with a small amount of cancer at the outset or in patients whose disease regression or progression was deemed minimal.
Serum TPA level, assayed by a hemagglutination inhibition reaction developed by Bjorklund et al. (6) , was based on the ability of TP A in the specimen to quantitatively neutralize anti-TPA antibodies that were adjusted to agglutinate 98-100% of sheep red blood cells labeled with TPA. Values below 0.09 U/ml are considered normal and those at this level or greater are considered elevated (I U TPA is equivalent to 0.17 Ilg TP A). Plasma CEA was measured by a radioimmunoassay procedure (7, 8) ; the normal range was 0-2.5 ng/ml plasma. 
RESULTS

TPA and CEA In Healthy Women and Patients With Breast Disease
We determined TPA and' CEA levels in 40 apparently healthy (age-matched) women volunteers ( with operable breast cancer, 5 (42%) were TPA-positive and I (8%) was CEA-positive. In 7 patients with inoperable cancer, 5 (71%) were TPA-positive and 3 (43%) were CEA-positive. Of 67 patients with metastatic breast cancer, 13 (19%) were both TPA-and CEA-negative, 47 (70%) were TPA-positive, and 41 (61%) CEA-positive.
In all subgroups except benign disease,' TP A and CEA values were significantly different. In the benign disease subgroup, CEA was "better" inasmuch as the TPA was "false positive" in 27% (P<0.05) . The differences of positivity of TPA in the healthy group versus primary cancer or metastatic group were statistically significant (both P<0.05).
The 67 patients with metastatic disease (table 2) were categorized: 20 patients with soft tissue metastasis, 26 with osseous, and 21 with visceral (pulmonary, hepatic, or cerebral) according to the dominant site of metastasis. The distributions of test results between the soft tissue and osseous groups were not different, but positi ves for both CEA and TP A significantly increased in the visceral as compared with the soft tissue group (P<0.05).
The distributions of individual TP A values in each subgroup recorded in table 3 illustrate that in healthy women or those with benign disease, the elevated values were in the low abnormal ranges. In the patients whose disease had metastasized, the test values were in the higher abnormal ranges and showed increased frequency of elevation. Table 4 gives the distribution of CEA values.
TPA and CEA In Post mastectomy Patients
TP A and CEA levels were also determined for 22 patients who previously had undergone curative mastectomy. All were free of metastatic disease at the time of assessment, and none developed metastases in the subsequent 6 months of follow-up. Of 11 patients with no axillary nodal involvement at mastectomy, 6 were TP A-positive and 3 were CEA-positive; 2 of these were both TP A-and CEA-positive. Results of testing another 11 patients with axillary nodal metastases at mastectomy revealed that 6 were TPA-positive and 3 were CEA-and TP A-positive. • NED = no evidence of disease. 
Serial TPA and CEA Studies In Patients With Metastatic Breast Cancer
Serial measurements of TPA and CEA were obtained for evaluation of their possible usefulness in determining the tumor response to palliative treatments for metastatic disease.
Thirty-nine patients were treated either by chemotherapy or hormone manipulations as described earlier.
The tumor continued to progress in 23, but 16 experienced regression of the metastatic disease. Table 5 summarizes the findings of the serial study. Markedly progressive disease was often accompanied by increasing marker values for both TPA and CEA. A minimal degree of progressive changes was more frequently associated with increased levels of TPA (6 of 13) compared with CEA levels (1 of 13). Marked clinical regression coincided with a decrease in TP A in 4 of 6 and in CEA in 3 of 6, whereas minimal regression was observed with a decrease in TP A in 0 of 10 and in CEA in 5 of 10.
DISCUSSION
We undertook this study to evaluate the usefulness of TPA in diagnosis and follow-up of patients with breast cancer. Simultaneously, we obtained an assessment of the relative merits of CEA. Generally, TPA performed nearly as well as CEA; however, CEA values were normal in all the patients with benign breast disease, whereas TPA values were abnormal in 27% of them. Some of these results are not dissimilar to those reported by Mendez-Botet et al. (2) . The TPA values in previously untreated primary cancer patients were elevated about one-half of the time. Because the elevated value was observed only in 42% of the patients with operable cancer, it seems to have limited value as a tool for early diagnosis of breast cancer. TPA values in patients with metastatic breast cancer increased at a higher frequency and were significantly elevated. Thus the elevated TP A and CEA levels appear to be indicators of metastatic disease.
A few patients who were being followed after their mastectomies were tested for both markers. Despite their being free of metastatic disease at the time of sampling and in the subsequent 6 months, a significant number (12 of 22) had elevated TPA values. The clinical implication of these tests or correctness of the TPA values in these patients is not known at this time.
Serial studies show that elevated values for CEA correlate with the clinical event in our previous study (4) . In a group of patients, levels of TPA and CEA were tested at least twice 1 month apart in some and three to five times in others. Marked progressive changes were reflected in 70% and 80% of the patients with elevated values of TPA and CEA, respectively. Whereas with minimal progressive disease, TP A levels rose in 6 of 13 and remained unchanged in another 6 of 13, the CEA values in this group were unchanged in 10 of 13 patients.
Marked regressive changes may be accompanied by decreased TP A or CEA levels but not necessarily. CEA values declined in 5 of 10 and remained stationary in 4 of 10 patients with minimal tumor regression. TPA values declined in 0 of 10 and did not change in 7 of 10. Thus TPA and CEA did not always accurately correlate with clinical events. In the overall assessment as a tumor marker, TPA appears equal to CEA in most areas we analyzed in this study.
